Diamond Hill Capital Management Inc. Acquires Shares of 488,244 Endo International PLC (ENDP)

Diamond Hill Capital Management Inc. purchased a new position in shares of Endo International PLC (NASDAQ:ENDP) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 488,244 shares of the company’s stock, valued at approximately $5,454,000. Diamond Hill Capital Management Inc. owned about 0.22% of Endo International PLC at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of ENDP. Norges Bank acquired a new position in shares of Endo International PLC during the fourth quarter worth about $26,929,000. Macquarie Group Ltd. boosted its stake in shares of Endo International PLC by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock worth $107,000 after buying an additional 3,700 shares during the period. Americafirst Capital Management LLC purchased a new stake in shares of Endo International PLC during the first quarter worth about $286,000. Hartford Investment Management Co. purchased a new stake in shares of Endo International PLC during the first quarter worth about $1,363,000. Finally, Nationwide Fund Advisors boosted its stake in shares of Endo International PLC by 400.0% in the first quarter. Nationwide Fund Advisors now owns 343,874 shares of the company’s stock worth $3,838,000 after buying an additional 275,101 shares during the period. 93.00% of the stock is owned by hedge funds and other institutional investors.

Endo International PLC (NASDAQ ENDP) traded up 0.53% during midday trading on Friday, reaching $7.59. 8,959,667 shares of the company traded hands. The firm’s market capitalization is $1.69 billion. Endo International PLC has a one year low of $7.41 and a one year high of $24.93. The firm has a 50-day moving average price of $10.93 and a 200-day moving average price of $11.55.

Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.19. The firm had revenue of $875.73 million for the quarter, compared to the consensus estimate of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The company’s quarterly revenue was down 4.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.86 earnings per share. Equities analysts predict that Endo International PLC will post $3.51 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Diamond Hill Capital Management Inc. Acquires Shares of 488,244 Endo International PLC (ENDP)” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://stocknewstimes.com/2017/08/12/diamond-hill-capital-management-inc-invests-5-45-million-in-endo-international-plc-endp-updated.html.

Several brokerages have recently issued reports on ENDP. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Endo International PLC in a research note on Sunday, July 23rd. Vetr raised shares of Endo International PLC from a “strong sell” rating to a “sell” rating and set a $11.34 price objective on the stock in a research note on Wednesday, May 17th. William Blair reissued a “market perform” rating on shares of Endo International PLC in a research note on Wednesday, June 14th. Zacks Investment Research lowered shares of Endo International PLC from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Finally, Canaccord Genuity set a $14.00 price target on shares of Endo International PLC and gave the company a “hold” rating in a research note on Monday, May 22nd. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have issued a buy rating to the stock. Endo International PLC currently has an average rating of “Hold” and a consensus target price of $14.86.

In other Endo International PLC news, COO Terrance J. Coughlin purchased 20,000 shares of the stock in a transaction dated Thursday, August 10th. The shares were purchased at an average cost of $7.70 per share, with a total value of $154,000.00. Following the completion of the acquisition, the chief operating officer now directly owns 181,369 shares in the company, valued at approximately $1,396,541.30. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.50% of the company’s stock.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Institutional Ownership by Quarter for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply